Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
13.57
-0.01 (-0.07%)
At close: Mar 6, 2026, 4:00 PM EST
13.59
+0.02 (0.15%)
After-hours: Mar 6, 2026, 4:23 PM EST
Theravance Biopharma Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$828,113
Profits / Employee
$302,515
Market Cap
687.62M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 579 |
| Prime Medicine | 214 |
| uniQure | 209 |
| ProKidney | 204 |
| Kura Oncology | 192 |
| Lexicon Pharmaceuticals | 103 |
| AgomAb Therapeutics NV | 58 |
TBPH News
- 4 days ago - Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
- 4 days ago - Theravance plans strategic review, including possible sale, after drug trial failure - Reuters
- 4 days ago - Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript - Seeking Alpha
- 3 months ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire
- 3 months ago - Theravance Biopharma to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 months ago - Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire